These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30093568)

  • 1. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
    McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
    Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
    Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
    Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis.
    Branchford BR; Stalker TJ; Law L; Acevedo G; Sather S; Brzezinski C; Wilson KM; Minson K; Lee-Sherick AB; Davizon-Castillo P; Ng C; Zhang W; Neeves KB; Lentz SR; Wang X; Frye SV; Shelton Earp H; DeRyckere D; Brass LF; Graham DK; Di Paola JA
    J Thromb Haemost; 2018 Feb; 16(2):352-363. PubMed ID: 29045015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders.
    Gadiyar V; Patel G; Chen J; Vigil D; Ji N; Campbell V; Sharma K; Shi Y; Weiss MM; Birge RB; Davra V
    Front Immunol; 2023; 14():1135373. PubMed ID: 37545504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
    Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
    Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation.
    Zhou J; Yang A; Wang Y; Chen F; Zhao Z; Davra V; Suzuki-Inoue K; Ozaki Y; Birge RB; Lu Q; Wu Y
    Cell Commun Signal; 2018 Dec; 16(1):98. PubMed ID: 30541554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor.
    Yu Y; Jang M; Miyashiro J; Clark RF; Zhu GD; Gong J; Dai Y; Frey RR; Penning TD; Kim H; Lee HK; Kim JK; Ryu KM; Park SJ; Yoon T; Li T; Kurnick MD; Kapecki NJ; Li L; Gorman JV; Montgomery DA; Manaves V; Bromberg KD; Doktor SZ; Thakur A; Wang J; Smith HA; Buchanan FG; Ferguson DC; Torrent M; Jakob CG; Qiu W; Upadhyay AK; Martin RL; Lai A; Michaelides MR
    J Med Chem; 2024 Oct; 67(19):17000-17032. PubMed ID: 39283694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
    Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
    Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.
    Knubel KH; Pernu BM; Sufit A; Nelson S; Pierce AM; Keating AK
    Oncotarget; 2014 Mar; 5(5):1338-51. PubMed ID: 24658326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
    Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
    Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
    Linger RM; Cohen RA; Cummings CT; Sather S; Migdall-Wilson J; Middleton DH; Lu X; Barón AE; Franklin WA; Merrick DT; Jedlicka P; DeRyckere D; Heasley LE; Graham DK
    Oncogene; 2013 Jul; 32(29):3420-31. PubMed ID: 22890323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.
    Myers KV; Amend SR; Pienta KJ
    Mol Cancer; 2019 May; 18(1):94. PubMed ID: 31088471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors.
    Kong D; Tian Q; Chen Z; Zheng H; Stashko MA; Yan D; Earp HS; Frye SV; DeRyckere D; Kireev D; Graham DK; Wang X
    J Med Chem; 2024 Apr; 67(7):5866-5882. PubMed ID: 38556760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerating AXL targeting for TNBC therapy.
    Khera L; Lev S
    Int J Biochem Cell Biol; 2021 Oct; 139():106057. PubMed ID: 34403827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthritis.
    Gao L; He C; Yang A; Zhou H; Lu Q; Birge RB; Wu Y
    Cell Commun Signal; 2023 Aug; 21(1):195. PubMed ID: 37537628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
    Cummings CT; Zhang W; Davies KD; Kirkpatrick GD; Zhang D; DeRyckere D; Wang X; Frye SV; Earp HS; Graham DK
    Mol Cancer Ther; 2015 Sep; 14(9):2014-22. PubMed ID: 26162689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours.
    Dave F; Herrera K; Lockley A; van de Weijer LL; Henderson S; Sofela AA; Hook L; Adams CL; Ercolano E; Hilton DA; Maze EA; Kurian KM; Ammoun S; Hanemann CO
    Oncogene; 2024 Oct; 43(41):3049-3061. PubMed ID: 39179860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
    Kimani SG; Kumar S; Bansal N; Singh K; Kholodovych V; Comollo T; Peng Y; Kotenko SV; Sarafianos SG; Bertino JR; Welsh WJ; Birge RB
    Sci Rep; 2017 Mar; 7():43908. PubMed ID: 28272423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
    Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Coan JP; Pearson HE; Bahrar H; Fowler TL; Bednarz BP; Saha S; Yang D; Gill PS; Lingen MW; Saloura V; Villaflor VM; Salgia R; Kimple RJ; Wheeler DL
    Clin Cancer Res; 2015 Jun; 21(11):2601-12. PubMed ID: 25767293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.